5:20 PM
 | 
Mar 22, 2013
 |  BC Extra  |  Company News

CHMP backs Iclusig, Stribild, Xarelto label expansion

Among a number of positive opinions issued on Friday, EMA's CHMP recommended approval of an MAA for Iclusig ponatinib from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). The product is under accelerated assessment, with...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >